Drug resistance in leishmaniasis: Current drug-delivery systems and future perspectives

Future Medicinal Chemistry

Volumn 5, Issue 15, 2013, Pages 1877-1888

  Yasinzai, Masoom ^a   Khan, Momin ^a,b   Nadhman, Akhtar ^a   Shahnaz, Gul ^a  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b KHYBER MEDICAL UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIPROTOZOAL AGENT; BUTHIONINE SULFOXIMINE; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CYCLOSPORIN A; EFLORNITHINE; FLAVONOID; HORMONE DERIVATIVE; LIPOSOME; MILTEFOSINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NIOSOME; PENTAMIDINE; POLOXAMER; POLYMER; PRIMAQUINE; PROTEIN KINASE INHIBITOR; SESQUITERPENE; SOLID LIPID NANOPARTICLE; STIBOGLUCONATE SODIUM; VERAPAMIL;

BIOSYNTHESIS; DEFORMITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; DRUG TARGETING; DRUG TRANSPORT; EMULSION; HUMAN; LEISHMANIASIS; LIVER; NANOTECHNOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; SPLEEN; STEROL SYNTHESIS; UNSPECIFIED SIDE EFFECT;

ANTIPROTOZOAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG CARRIERS; DRUG RESISTANCE; EMULSIONS; HUMANS; LEISHMANIASIS; LIPOSOMES; NANOPARTICLES; POLYMERS;

EID: 84886535279     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.143     Document Type: Review

References (116)

1. Minodier P, Retornaz K, Horelt A, Garnier JM. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam. Clin. Pharmacol. 17(2), 183-188 (2003
2. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59(6), 505-521 (2007
3. Santos DO, Coutinho CE, Madeira MF et al. Leishmaniasis treatment-A challenge that remains: A review. Parasitol. Res. 103(1), 1-10 (2008
4. Van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis. 10(3), 184-194 (2010
5. Di Giorgio C, Faraut-Gambarelli F, Imbert A, Minodier P, Gasquet M, Dumon H. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J. Antimicrob. Chemother. 44(1), 71-76 (1999
6. Sundar S, Sinha PR, Agrawal NK et al. A cluster of cases of severe cardiotoxicity among kala-Azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg. 59(1), 139-143 (1998
7. De Lalla F, Pellizzer G, Gradoni L, Vespignani M, Franzetti M, Stecca C. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 16(5), 730-731 (1993
8. Oliveira LF, Schubach AO, Martins MM et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 118(2), 87-96 (2011
9. Rodrigues ML, Costa RS, Souza CS, Foss NT, Roselino AM. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev. Inst. Med. Trop. Sao Paulo 41(1), 33-37 (1999
10. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 366(9496), 1561-1577 (2005
11. Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. Treatment of paediatric visceral leishmaniasis: Amphotericin B or pentavalent antimony compounds? Int. J. Antimicrob. Agents 25(1), 26-30 (2005
12. Minodier P, Robert S, Noel G, Blanc P, Retornaz K, Garnier JM. First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France. Arch. Pediatr. 12(7), 1102-1108 (2005
13. Roy P, Das S, Bera T, Mondol S, Mukherjee A. Andrographolide nanoparticles in leishmaniasis: Characterization and in vitro evaluations. Int. J. Nanomedicine 5, 1113-1121 (2010
14. Lopes R, Eleutério CV, Gonçalves LMD, Cruz MEM, Almeida AJ. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur. J. Pharm. Sci. 45(4), 442-450 (2012
15. Van De Ven H, Vermeersch M, Vandenbroucke RE et al. Intracellular drug delivery in Leishmania-infected macrophages: Evaluation of saponin-loaded PLGA nanoparticles. J. Drug Target. 20(2), 142-154 (2012
16. Davidson RN, Croft SL, Scott A, Maini M, Moody AH, Bryceson AD. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337(8749), 1061-1062 (1991
17. Gradoni L, Davidson RN, Orsini S, Betto P, Giambenedetti M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J. Drug Target. 1(4), 311-316 (1993
18. Amato VS, Rabello A, Rotondo-Silva A et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 92(2), 127-132 (2004
19. Black CD, Watson GJ, Ward RJ. The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans. R Soc. Trop. Med. Hyg. 71(6), 550-552 (1977
20. Alving CR, Steck EA, Chapman WL Jr et al. Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs. Proc. Natl Acad. Sci. USA 75(6), 2959-2963 (1978
21. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19(11), 502-508 (2003
22. Goyeneche-Patino DA, Valderrama L, Walker J, Saravia NG. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. Antimicrob. Agents Chemother. 52(12), 4503-4506 (2008
23. Flórez AF, Watowich S, Muskus C. Current Advances in Computational Strategies for Drug Discovery in Leishmaniasis. In: Current Topics in Tropical Medicine. Rodriguez-Morales A (Ed.). InTech Open, Rijeka, Croatia. 253-272 (2012
24. Jeddi F, Piarroux R, Mary C. Antimony resistance in Leishmania, focusing on experimental research. J. Trop. Med. 2011, 695382 (2011
25. Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 5(2), 167-173 (1998
26. Basselin M, Denise H, Coombs GH, Barrett MP. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents Chemother. 46(12), 3731-3738 (2002
27. Gray KC, Palacios DS, Dailey I et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl Acad. Sci. USA 109(7), 2234-2239 (2012
28. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42(2), 352-357 (1998
29. Leandro C, Campino L. Leishmaniasis: Efflux pumps and chemoresistance. Int. J. Antimicrob. Agents 22(3), 352-357 (2003
30. Legare D, Hettema E, Ouellette M. The P-glycoprotein-related gene family in Leishmania. Mol. Biochem. Parasitol. 68(1), 81-91 (1994
31. Gueiros-Filho FJ, Viola JP, Gomes FC et al. Leishmania amazonensis: Multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Exp. Parasitol. 81(4), 480-490 (1995
32. Henderson DM, Sifri CD, Rodgers M, Wirth DF, Hendrickson N, Ullman B. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol. Cell. Biol. 12(6), 2855-2865 (1992
33. Seifert K, Matu S, Perez-Victoria FJ, Castanys S, Gamarro F, Croft SL. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 22(4), 380-387 (2003
34. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 279(38), 39925-39932 (2004
35. Mukhopadhyay R, Dey S, Xu N et al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl Acad. Sci. USA 93(19), 10383-10387 (1996
36. Arana FE, Perez-Victoria JM, Repetto Y, Morello A, Castanys S, Gamarro F. Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica. Biochem. Pharmacol. 56(9), 1201-1208 (1998
37. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. Co-Amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 16(11), 3057-3065 (1997
38. Haimeur A, Guimond C, Pilote S et al. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol. Microbiol. 34(4), 726-735 (1999
39. Legare D, Richard D, Mukhopadhyay R et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-Thiol transporter ATPase. J. Biol. Chem. 276(28), 26301-26307 (2001
40. Khan MO. Trypanothione reductase: A viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design. Drug Target. Insights 2, 129-146 (2007
41. Tavares J, Ouaissi A, Lin PK, Tomas A, Cordeiro-Da-Silva A. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int. J. Parasitol. 35(6), 637-646 (2005
42. Vannier-Santos MA, Menezes D, Oliveira MF, De Mello FG: The putrescine analogue 1,4-diamino-2-butanone affects polyamine synthesis, transport, ultrastructure and intracellular survival in Leishmania amazonensis. Microbiology 154(Pt 10), 3104-3111 (2008
43. Roberts SC, Jiang Y, Gasteier J et al. Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs. Antimicrob. Agents Chemother. 51(2), 438-445 (2007
44. Kandpal M, Tekwani BL, Chauhan PM, Bhaduri AP. Correlation between inhibition of growth and arginine transport of Leishmania donovani promastigotes in vitro by diamidines. Life Sci. 59(7), L75-L80 (1996
45. Heby O, Persson L, Rentala M. Targeting the polyamine biosynthetic enzymes: A promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids 33(2), 359-366 (2007
46. Coward JK, Pegg AE. Specific multisubstrate adduct inhibitors of aminopropyltransferases and their effect on polyamine biosynthesis in cultured cells. Adv. Enzyme Regul. 26, 107-113 (1987
47. Khomutov AR. Inhibition of enzymes of polyamine biosynthesis by substrate-like O-substituted hydroxylamines. Biochemistry 67(10), 1159-1167 (2002
48. Singh N, Kumar M, Singh RK. Leishmaniasis: Current status of available drugs and new potential drug targets. Asian Pac. J. Trop. Med. 5(6), 485-497 (2012
49. Chawla B, Madhubala R. Drug targets in Leishmania. J. Parasit. Dis. 34(1), 1-13 (2010
50. Fernandes Rodrigues JC, Concepcion JL, Rodrigues C, Caldera A, Urbina JA, De Souza W. In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: Antiproliferative, biochemical, and ultrastructural effects. Antimicrob. Agents Chemother. 52(11), 4098-4114 (2008
51. Vannier-Santos MA, Urbina JA, Martiny A, Neves A, De Souza W. Alterations induced by the antifungal compounds ketoconazole and terbinafine in Leishmania. J. Eukaryot. Microbiol. 42(4), 337-346 (1995
52. Magaraci F, Jimenez CJ, Rodrigues C et al. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J. Med. Chem. 46(22), 4714-4727 (2003
53. Lorente SO, Rodrigues JC, Jimenez Jimenez C et al. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother. 48(8), 2937-2950 (2004
54. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother. 43(12), 2910-2914 (1999
55. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin. Infect. Dis. 31(4), 1104-1107 (2000
56. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6(11), 849-854 (2001
57. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol. Res. 48(4), 347-359 (2003
58. Krishna R, Mayer LD. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: Recent advances in the design of selective MDR modulators. Curr. Med. Chem. Anticancer Agents 1(2), 163-174 (2001
59. Mckeegan KS, Borges-Walmsley MI, Walmsley AR. Structural understanding of efflux-mediated drug resistance: Potential routes to efflux inhibition. Curr. Opin. Pharmacol. 4(5), 479-486 (2004
60. Serrano-Martin X, Payares G, De Lucca M, Martinez JC, Mendoza-Leon A, Benaim G. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob. Agents Chemother. 53(12), 5108-5113 (2009
61. Essodaigui M, Frezard F, Moreira ES, Dagger F, Garnier-Suillerot A. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps. Mol. Biochem. Parasitol. 100(1), 73-84 (1999
62. Chiquero MJ, Perez-Victoria JM, O'Valle F et al. Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line. Biochem. Pharmacol. 55(2), 131-139 (1998
63. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 25(3), 500-511 (2008
64. Hornof MD, Kast CE, Bernkop-Schnurch A. In vitro evaluation of the viscoelastic properties of chitosan-Thioglycolic acid conjugates. Eur. J. Pharm. Biopharm. 55(2), 185-190 (2003
65. Shahnaz G, Perera G, Sakloetsakun D, Rahmat D, Bernkop-Schnurch A. Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran-cysteine conjugate. J. Control. Release 144(1), 32-38 (2010
66. Kast CE, Valenta C, Leopold M, Bernkop-Schnurch A. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J. Control. Release 81(3), 347-354 (2002
67. Moghaddam FA, Atyabi F, Dinarvand R. Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine 5(2), 208-215 (2009
68. Martien R, Loretz B, Thaler M, Majzoob S, Bernkop-Schnurch A. Chitosan-Thioglycolic acid conjugate: An alternative carrier for oral nonviral gene delivery? J. Biomed. Mater. Res. A 82(1), 1-9 (2007
69. Foger F, Schmitz T, Bernkop-Schnurch A. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27(23), 4250-4255 (2006
70. Foger F, Hoyer H, Kafedjiiski K, Thaurer M, Bernkop-Schnurch A. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27(34), 5855-5860 (2006
71. Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release 111(1-2), 41-46 (2006
72. Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J. Pharm. Pharmacol. 40(3), 161-165 (1988
73. Nelson KG, Bishop JV, Ryan RO, Titus R. Nanodisk-Associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob. Agents Chemother. 50(4), 1238-1244 (2006
74. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J. Drug Target. 15(6), 437-444 (2007
75. Doroud D, Vatanara A, Zahedifard F et al. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: Characterization and in vitro evaluations. J. Pharm. Pharm. Sci. 13(3), 320-335 (2010
76. Shahnaz G, Vetter A, Barthelmes J et al. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: Bioavailability and pharmacokinetic characterization. Int. J. Pharm. 428(1-2), 164-170 (2012
77. Nan A, Croft SL, Yardley V, Ghandehari H. Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J. Control. Release 94(1), 115-127 (2004
78. Nicoletti S, Seifert K, Gilbert IH. N-(2-hydroxypropyl)methacrylamide- Amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int. J. Antimicrob. Agents 33(5), 441-448 (2009
79. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90(6), 667-680 (2001
80. New RR, Chance ML, Thomas SC, Peters W. Antileishmanial activity of antimonials entrapped in liposomes. Nature 272(5648), 55-56 (1978
81. New RRC, Chance ML, Heath S. The treatment of experimental cutaneous leishmaniasis with liposome-entrapped pentostam. Parasitology 83(03), 519-527 (1981
82. New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8(5), 371-381 (1981
83. Adler-Moore J, Proffitt RT. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 1, 21-30 (2002
84. Minodier P, Retornaz K, Horelt A, Garnier JM. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam. Clin. Pharmacol. 17(2), 183-188 (2003
85. Espuelas S, Legrand P, Loiseau PM, Bories C, Barratt G, Irache JM. In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob. Agents Chemother. 44(8), 2190-2192 (2000
86. Davidson RN, Di Martino L, Gradoni L et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial. Q J. Med. 87(2), 75-81 (1994
87. Torchilin VP. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 2(1), 65-115 (1985
88. Sihorkar V, Vyas SP. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J. Pharm. Pharm. Sci. 4(2), 138-158 (2001
89. Agrawal AK, Agrawal A, Pal A, Guru PY, Gupta CM. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Target. 10(1), 41-45 (2002
90. Basu MK. Liposomal delivery of antileishmanial agents. J. Appl. Res. 5(1), 221-236 (2005
91. Kole L, Das L, Das PK. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J. Infect. Dis. 180(3), 811-820 (1999
92. Shimizu Y, Yamakami K, Gomi T et al. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg. Med. Chem. 11(7), 1191-1195 (2003
93. Sarkar S, Mandal S, Sinha J, Mukhopadhyay S, Das N, Basu MK. Quercetin: Critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J. Drug Target. 10(8), 573-578 (2002
94. Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S, Basu MK. Harmine: Evaluation of its antileishmanial properties in various vesicular delivery systems. J. Drug Target. 12(3), 165-175 (2004
95. Hu C, Rhodes DG. Proniosomes: A novel drug carrier preparation. Int. J. Pharm. 185(1), 23-35 (1999
96. Carter KC, Dolan TF, Alexander J, Baillie AJ, Mccolgan C. Visceral leishmaniasis: Drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol. 41(2), 87-91 (1989
97. Pardakhty A, Shakibaie M, Daneshvar H, Khamesipour A, Mohammadi-Khorsand T, Forootanfar H. Preparation and evaluation of niosomes containing autoclaved Leishmania major: A preliminary study. J. Microencapsul. 29(3), 219-224 (2012
98. Lezama-Davila CM. Vaccination of C57BL/10 mice against cutaneous leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: A novel approach. Mem. Inst. Oswaldo Cruz 94(1), 67-70 (1999
99. Narayanaswami V, Maiorano JN, Dhanasekaran P et al. Helix orientation of the functional domains in apolipoprotein e in discoidal high density lipoprotein particles. J. Biol. Chem. 279(14), 14273-14279 (2004
100. Romero EL, Morilla MJ. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin. Drug Deliv. 5(7), 805-823 (2008
101. Veerareddy PR, Vobalaboina V, Nahid A. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 59(3), 194-197 (2004
102. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur. J. Pharm. Biopharm. 50(1), 161-177 (2000
103. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3), 165-196 (2001
104. Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharm. Res. 23(7), 1417-1450 (2006
105. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 28(1), 1-13 (2002
106. Mbela TKM, Poupaert JH, Dumont P. Poly(diethylmethylidene malonate) nanoparticles as primaquine delivery system to liver. Int. J. Pharm. 79(1-3), 29-38 (1992
107. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 26(5), 1025-1058 (2009
108. Gaspar R, Preat V, Opperdoes FR, Roland M. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: Activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm. Res. 9(6), 782-787 (1992
109. Rodrigues JM, Jr., Croft SL, Fessi H, Bories C, Devissaguet JP. The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop. Med. Parasitol. 45(3), 223-228 (1994
110. Espuelas MS, Legrand P, Loiseau PM, Bories C, Barratt G, Irache JM. In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon- caprolactone) nanospheres. J. Drug Target. 10(8), 593-599 (2002
111. Durand R, Paul M, Rivollet D, Houin R, Astier A, Deniau M. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Int. J. Parasitol. 27(11), 1361-1367 (1997
112. Torres-Santos EC, Rodrigues JM Jr, Moreira DL, Kaplan MA, Rossi-Bergmann B. Improvement of in vitro and in vivo antileishmanial activities of 2́, 6́-dihydroxy-4́-methoxychalcone by entrapment in poly(d,l-lactide) nanoparticles. Antimicrob. Agents Chemother. 43(7), 1776-1778 (1999
113. Gaspar R, Opperdoes FR, Preat V, Roland M. Drug targeting with polyalkylcyanoacrylate nanoparticles: In vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86(1), 41-49 (1992
114. Basu MK, Lala S. Macrophage specific drug delivery in experimental leishmaniasis. Curr. Mol. Med. 4(6), 681-689 (2004
115. Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J. Antimicrob. Chemother. 44(6), 791-794 (1999
116. Sinha J, Raay B, Das N et al. Bacopasaponin C: Critical evaluation of anti-leishmanial properties in various delivery modes. Drug Deliv. 9(1), 55-62 (2002)